2-Pyridinecarbonitrile, 6-(2,3-dihydro-2-methyl-3-oxo-1H-isoindol-5-yl)-5-[1-[(1-methylcyclopentyl)methyl]-1H-pyrazol-4-yl]-
Alzheimer's Disease
Merck Sharp & Dohme LLCSmall moleculePhase 1Dormant
CC
42/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 73/ 100
Competitive context
317 Active assets in the Alzheimer's Disease cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
4-((1E)-2-(6-(2-)2-(2-FLUOROETHOXY)ETHOXY)ETHOXY)PYRIDIN-3-YL)ETHENYL)-N-METHYLBENZENAMINE Akiva Mintz | Phase 4 | BBB |
Namenda Carnot Laboratories | Phase 4 | BBB |
Cipralex NYU Langone Health | Phase 4 | BBB |
Rivastigmine Anhui Provincial Hospital | Phase 4 | BBB |
Sertraline AstraZeneca | Phase 4 | BBB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →